HER2-Positive Breast Cancer Market Analysis

The HER2-Positive Breast Cancer Market is estimated to be valued at USD 10.70 bn in 2024 and is expected to reach USD 12.03 bn by 2031, growing at a compound annual growth rate (CAGR) of 2.23% from 2024 to 2031.

The market is witnessing positive growth trends over the past few years. The increasing prevalence of breast cancer worldwide due to growing obesity rates and lifestyle changes is expected to be a key factor driving the growth of this market. Additionally, rising awareness programs by governments and non-profit organizations regarding early screening and treatment is also contributing to the growth. The HER2-positive breast cancer market focuses on treatments targeting the overexpression of the HER2 protein, which promotes aggressive tumor growth. This type of cancer accounts for about 15-20% of all breast cancers. The market has grown significantly due to advancements in targeted therapies like trastuzumab (Herceptin), pertuzumab, and antibody-drug conjugates such as T-DM1 (Kadcyla) and trastuzumab deruxtecan. Increasing R&D investments, a rising global incidence of breast cancer, and the development of biosimilars are driving market expansion. However, high treatment costs and resistance to therapies remain challenges for patients and healthcare providers alike.